Mikhail Blagosklonny Insight on Rapamycin and Oncology

Mikhail Blagosklonny is a renowned oncologist, professor, and a philanthropist. His passion for medical health has driven him into research specializing in cancer and aging process. He has devoted his time and resources to researching the correlation between old age and cancer. Mikhail contribution in this field is an inspiration to many including his student and colleagues. Mikhail Blagosklonny attended the First Pavlov State Medical University of St. Petersburg where studied M.D. in internal medicine. Later he earned his Ph.D. in cardiology and experimental medicine. He has worked as associate professor in medicine and then the senior scientist at Ordway Research Institute, Albany, New York. Currently, Mikhail Blagosklonny serves at Roswell Park Cancer Institute, New York, as a professor of oncology. Also, Mikhail is the Editor in Chief of the Oncotarget medical journal.

Rapamycin Healing Properties

Rapamycin or Sirolimus is a drug known in the market as Rapamune. Discovered in 1972 from bacterium samples, Sirolimus drug is known for preventing rejection in organ transplant. At first, Sirolimus was utilized as anti-fungal before the discovery of its high medicinal value. According to Mikhail Blagosklonny, Rapamycin has some of the following healing properties. Rapamycin contains immunosuppressant properties. Rapamune portrays a much less toxicity level towards kidney in the case of a transplant than any other drug. This low level is ideal for the patient diagnosed with the hemolytic-uremic syndrome. This rare condition is brought about the complexity of kidney failure, anemia, and low platelet count. Also, Rapamune is used to treat Lymphangioleiomyomatosis, a disease affecting women at the stage of bearing children.

Sirolimus is also used by doctors for coronary stents coating to hinder the re-stenosis occurring.The Sirolimus antiproliferative properties are perfect for the treatment of cancer. According to Blagosklonny, the drug can increase the body immune response towards tumors. Additionally, the research done patients with Tuberous Sclerosis Complex and Facial angiofibromas problem were cured after Rapamycin treatment. Mikhail Blagosklonny state that other investigations are in the prime stage concerning the treatment of Alzheimer diseases, Muscular Dystrophy, and Systemic Lupus Erythematosus by Rapamycin. Also, there is the steadfast belief from the successful research conducted on mice that Rapamycin can prolong the life of people.

Mikhail Plans for Oncology

Mikhail Blagosklonny dedication for the treatment of cancer has been enormous. His name is well known to scientific and research field of oncology. He has conducted numerous analyses, published many articles especially in Oncotarget journal and lectured as Professor of oncology for many years. His particular insight published in impactjournal.com elicited much interest in the world of medicine. Mikhail expectations of effectively and thoroughly treating cancer are an all-time high. He is committed to eliminating the cancerous cells from the body without affecting the crucial and healthy cells.His progress and interest within the field bring hopes as well as inspiration to many, more so to people living with cancer. Mikhail Blagosklonny expectations are thatt in future, cancer and deadly diseases treatment will be way easier as well as being affordable. His research on connections between aging and cancer is well progressing.